Literature DB >> 9062401

Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors.

S L Davies1, J Bergh, A L Harris, I D Hickson.   

Abstract

We have studied the relationship between expression of genes implicated in mediating resistance to cleavable complex-forming topoisomerase II (topo II) inhibitors and cellular sensitivity to ICRF-159, a 'catalytic' inhibitor of topo II. Overexpression of the membrane transporters, P-glycoprotein and multidrug resistance-related protein (MRP), or down-regulation of topo IIalpha and/or -beta, did not confer ICRF-159 resistance. Indeed, marked topo IIalpha down-regulation appeared to be associated with collateral sensitivity to ICRF-159. Our results indicate that the resistance mechanisms that pertain to cleavable complex-forming topo II inhibitors and ICRF-159 are distinct. The evidence presented here suggests that topo IIalpha, not topo IIbeta, is more likely to be the major in vivo target for ICRF-159.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9062401      PMCID： PMC2063389          DOI： 10.1038/bjc.1997.146

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  23 in total

1.  Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.

Authors:  K Tanabe; Y Ikegami; R Ishida; T Andoh
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

2.  Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins.

Authors:  S M Davies; C N Robson; S L Davies; I D Hickson
Journal:  J Biol Chem       Date:  1988-11-25       Impact factor: 5.157

3.  Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines.

Authors:  A M Fry; C M Chresta; S M Davies; M C Walker; A L Harris; J A Hartley; J R Masters; I D Hickson
Journal:  Cancer Res       Date:  1991-12-15       Impact factor: 12.701

4.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

5.  Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors.

Authors:  J A Moscow; C R Fairchild; M J Madden; D T Ransom; H S Wieand; E E O'Brien; D G Poplack; J Cossman; C E Myers; K H Cowan
Journal:  Cancer Res       Date:  1989-03-15       Impact factor: 12.701

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity.

Authors:  B Glisson; R Gupta; S Smallwood-Kentro; W Ross
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

8.  Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells.

Authors:  G Batist; A Tulpule; B K Sinha; A G Katki; C E Myers; K H Cowan
Journal:  J Biol Chem       Date:  1986-11-25       Impact factor: 5.157

9.  Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.

Authors:  S Houlbrook; C M Addison; S L Davies; J Carmichael; I J Stratford; A L Harris; I D Hickson
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

10.  Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24.

Authors:  J R Jenkins; P Ayton; T Jones; S L Davies; D L Simmons; A L Harris; D Sheer; I D Hickson
Journal:  Nucleic Acids Res       Date:  1992-11-11       Impact factor: 16.971
View more
  3 in total

Review 1.  Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.

Authors:  V Ashutosh Rao
Journal:  Antioxid Redox Signal       Date:  2012-10-26       Impact factor: 8.401

2.  Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II.

Authors:  Ahad A Sadiq; Manish R Patel; Blake A Jacobson; Marco Escobedo; Keith Ellis; Lisa M Oppegard; Hiroshi Hiasa; Robert A Kratzke
Journal:  Invest New Drugs       Date:  2009-01-10       Impact factor: 3.850

3.  Canonical non-homologous end joining in mitosis induces genome instability and is suppressed by M-phase-specific phosphorylation of XRCC4.

Authors:  Masahiro Terasawa; Akira Shinohara; Miki Shinohara
Journal:  PLoS Genet       Date:  2014-08-28       Impact factor: 5.917
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.